July 25, 2016 1:46 PM ET

Healthcare Equipment and Supplies

Company Overview of Immucor, Inc.

Company Overview

Immucor Inc. and its subsidiaries develop, manufacture, and sell reagents and automated systems used primarily by hospitals, clinical labs, and blood banks in tests to detect and identify certain properties of the cell and serum components of human blood before blood transfusions. The company’s reagent product lines include abo blood grouping and Rh blood typing reagents, anti-human globulin serums, reagent red blood cells, rare serums, antibody potentiators, quality control systems, monoclonal antibody-based reagents, technical proficiency systems, and a fetal bleed screen kit, as well as Capture-P, Capture-R, Capture-CMV, Capture-S, and Capture-R Select reagents. These are used in tests to...

3130 Gateway Drive

PO Box 5625

Norcross, GA 30091

United States

Founded in 1982

1,090 Employees

Phone:

770-441-2051

Fax:

770-441-3807

Key Executives for Immucor, Inc.

Chairman of the Board, Chief Executive Officer and President
Age: 53
Chief Financial Officer, Chief Accounting Officer, Vice President and Vice President of International Transfusion Diagnostics
Age: 54
Vice President of Operations
Vice President of International Finance
Age: 59
Compensation as of Fiscal Year 2016.

Immucor, Inc. Key Developments

Immucor, Inc., Q3 2016 Fixed Income Call, Apr 21, 2016

Immucor, Inc., Q3 2016 Fixed Income Call, Apr 21, 2016

Immucor, Inc. Announces FDA Clearance for the Latest Release of ImmuLINK® (V1.7)

Immucor, Inc. announced FDA clearance for the latest release of ImmuLINK® (v1.7), the company’s centralized data management solution that supports greater testing efficiency and safety within transfusion medicine. The latest release of ImmuLINK includes a molecular module that helps users manage the workflow associated with running Immucor’s PreciseType HEA test, reducing manual data entry and significantly increasing the number of tests a lab may perform and report. The PreciseType HEA test is the first and only FDA-approved molecular typing solution and is eligible for reimbursement across the U.S. ImmuLINK v1.7 enhancements, specifically tailored to PreciseType HEA users, include: Antigen transfer interface to eliminate manual entry of antigen results into a laboratory information system (LIS); Barcode capability to assist with sample tracking during DNA extraction on the QIAcube; and a Molecular driver to help users set up PreciseType HEA. Additionally, ImmuLINK v1.7 now aggregates all serology and molecular IVD test results from the Echo®, NEO® and PreciseType platforms. ImmuLINK v1.7 generates a single report with a complete donor or patient testing history.

Immucor Presents at J.P. Morgan Global High Yield & Leveraged Finance Conference, Mar-01-2016 09:40 AM

Immucor Presents at J.P. Morgan Global High Yield & Leveraged Finance Conference, Mar-01-2016 09:40 AM. Venue: Loews Miami Beach Hotel, Miami Beach, Florida, United States. Speakers: Jeffrey Binder, President & CEO.

Similar Private Companies By Industry

Company Name Region
.decimal, Inc. United States
20/20 GeneSystems, Inc. United States
20/20 Imaging LLC United States
21st Century Scientific, Inc. United States
21X Corporation United States

Recent Private Companies Transactions

Type
Date
Target
Merger/Acquisition
March 4, 2016
Sirona Genomics, Inc.
 

The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content. For inquiries, please contact Capital IQ directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Immucor, Inc., please visit www.immucor.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.